Age-dependent inverse correlations in CSF and plasma amyloid-β(1-42) concentrations prior to amyloid plaque deposition in the brain of 3xTg-AD mice

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Cho, Soo Min ^a,b   Lee, Sejin ^a,b   Yang, Seung Hoon ^a   Kim, Hye Yun ^a,b,c   Lee, Michael Jisoo ^a,g   Kim, Hyunjin Vincent ^a,b   Kim, Jiyoon ^a,b   Baek, Seungyeop ^a,f   Yun, Jin ^a,b   Kim, Dohee ^a,f   Kim, Yun Kyung ^a,b   Cho, Yakdol ^d   Woo, Jiwan ^d   Kim, Tae Song ^e   Kim, YoungSoo ^a,b  

^a Department of Pharmacology   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c GoshenBiotech   (South Korea)

^d Department of Pharmacology   (South Korea)

^e Korea Institute of Science and Technology   (South Korea)

^f Yonsei University   (South Korea)

^g California Northstate University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL; BLOOD; BLOOD BRAIN BARRIER; BRAIN; CEREBROSPINAL FLUID; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PHOSPHORYLATION; PROTEIN TRANSPORT; TRANSGENIC MOUSE;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PLAQUE, AMYLOID; PROTEIN TRANSPORT;

EID: 84957595802     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20185     Document Type: Article

References (32)

1. Graff-Radford, N. R. et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64, 354-362, doi: 10.1001/archneur.64.3.354 (2007).
2. Schupf, N. et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci USA 105, 14052-14057, doi: 10.1073/pnas.0805902105 (2008).
3. Schupf, N. et al. Change in plasma Ass peptides and onset of dementia in adults with Down syndrome. Neurology 75, 1639-1644, doi: 10.1212/WNL.0b013e3181fb448b (2010).
4. Seppala, T. T. et al. Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry 81, 1123-1127, doi: 10.1136/jnnp.2010.205757 (2010).
5. Yaffe, K. et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305, 261-266, doi: 10.1001/jama.2010.1995 (2011).
6. Koyama, A. et al. Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol 69, 824-831, doi: 10.1001/archneurol.2011.1841 (2012).
7. Locascio, J. J. et al. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol 65, 776-785, doi: 10.1001/archneur.65.6.776 (2008).
8. Sundelof, J. et al. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol 65, 256-263, doi: 10.1001/archneurol.2007.57 (2008).
9. van Oijen, M. et al. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5, 655-660, doi: 10.1016/S1474-4422(06)70501-4 (2006).
10. Mehta, P. D. et al. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57, 100-105, doi: 10.1001/archneur.57.1.100. (2000).
11. McKhann, G. et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944, doi: http://dx.doi.org/10.1212/WNL.34.7.939 (1984).
12. Jack, C. R., Jr. et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132, 1355-1365, doi: 10.1093/brain/awp062 (2009).
13. Jack, C. R., Jr. et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128, doi: 10.1016/S1474-4422(09)70299-6 (2010).
14. Maia, L. F. et al. Changes in amyloid-beta and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med 5, 194re192, doi: 10.1126/scitranslmed.3006446 (2013).
15. Maia, L. F. et al. Increased CSF Abeta during the very early phase of cerebral Abeta deposition in mouse models. EMBO Mol Med 7, 895-903, doi: 10.15252/emmm.201505026 (2015).
16. Fagan, A. M. et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med 6, 226ra230, doi: 10.1126/scitranslmed.3007901 (2014).
17. Billings, L. M. et al. Learning decreases A beta∗56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. J Neurosci 27, 751-761, doi: 10.1523/JNEUROSCI.4800-06.2007 (2007).
18. Billings, L. M. et al. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45, 675-688, doi: 10.1016/j.neuron.2005.01.040 (2005).
19. Gimenez-Llort, L. et al. Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. Neurosci Biobehav Rev 31, 125-147, doi: 10.1016/j.neubiorev.2006.07.007 (2007).
20. Oddo, S. et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421, doi: 10.1016/S0896-6273(03)00434-3 (2003).
21. Oh, K. J. et al. Staging of Alzheimer's pathology in triple transgenic mice: a light and electron microscopic analysis. Int J Alzheimers Dis 2010, 1-24, doi: 10.4061/2010/780102 (2010).
22. Cho, S. M. et al. Correlations of amyloid-beta concentrations between CSF and plasma in acute Alzheimer mouse model. Sci Rep 4, 6777, doi: 10.1038/srep06777 (2014).
23. Kim, H. Y. et al. EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-beta oligomers and plaques. Nat Commun 6, 8997, doi: 10.1038/ncomms9997 (2015).
24. Liu, L. & Duff, K. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J Vis Exp, doi: 10.3791/960 (2008).
25. Kuo, Y. M. et al. The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. Mol Med 7, 609-618 (2001).
26. Jancso, G. et al. Beta-amyloid (1-42) peptide impairs blood-brain barrier function after intracarotid infusion in rats. Neurosci Lett 253, 139-141, doi: 10.1016/S0304-3940(98)00622-3 (1998).
27. Carroll, J. C. et al. Sex differences in beta-amyloid accumulation in 3xTg-AD mice: role of neonatal sex steroid hormone exposure. Brain Res 1366, 233-245, doi: 10.1016/j.brainres.2010.10.009 (2010).
28. McCullough, L. D. et al. NIH initiative to balance sex of animals in preclinical studies: generative questions to guide policy, implementation, and metrics. Biol Sex Differ 5, 15, doi: 10.1186/s13293-014-0015-5 (2014).
29. Morris, J. C. et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) 2, 975-984, doi: 10.4155/cli.12.93 (2012).
30. Kim, H. Y. et al. Taurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's disease. Sci Rep 4, 7467, doi: 10.1038/srep07467 (2014).
31. Eisele, Y. S. et al. Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci USA 106, 12926-12931, doi: 10.1073/pnas.0903200106 (2009).
32. Wilcock, D. M. et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 23, 3745-3751 (2003).